DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • South Korea
  • /
  • Software
Author Program NEWCreate Narrative
A040350 logo

CreoSG Co.,Ltd. Stock Price

KOSDAQ:A040350 Community·₩85.6b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

A040350 Share Price Performance

₩4,320.00
410.00 (10.49%)
​
₩4,320.00
410.00 (10.49%)
​
Price ₩4,320.00
Fri, 11 Sep 26
Share Pricen/a

A040350 Community Narratives

There are no narratives available yet.
Create Narrative
There are no community narratives available.

Trending Discussion

No trending discussion available.

Recently Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Slight risk with worrying balance sheet.

4 Risks
0 Rewards
View Full Analysis

CreoSG Co.,Ltd. Key Details

₩11.9b

Revenue

₩8.0b

Cost of Revenue

₩3.9b

Gross Profit

₩7.0b

Other Expenses

-₩3.2b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-159.87
32.49%
-26.59%
66.6%
View Full Analysis

About A040350

Founded
1997
Employees
41
CEO
SangGyun Lee
WebsiteView website
www.creosg.com

CreoSG Co.,Ltd., together with its subsidiaries, develops software solutions for financial institutions in South Korea. It operates through Solution, Product Distribution, and New Drug and Vaccine Development divisions. The company offers bank automation and network control system for Korea (BANCS-K). It also provides IT outsourcing services, including information system development; ERP development and operation; sales system development and operation; vehicle management system development and operation; and operation of website and shopping mall integrated management systems. In addition, the company distributes IT products, such as LED monitors, TV monitors, solid-state drives, computers, laptops, and printers. Further, it engages in the development, production, and sales of infectious disease vaccines, therapeutic vaccines, and vaccines developed for alternative routes of administration. The company develops its products based on its VSV vector technology. Its product pipeline includes SAV001, a product candidate in Phase 1 clinical trials to treat HIV/AIDS; and product candidates in preclinical trials for the treatment of COVID-19, hepatitis C, Ebola virus, MERS virus, Zika virus, and SFTS/HFRS. The company was formerly known as CUROCOM Co., Ltd. and changed its name to CreoSG Co.,Ltd. in March 2024. CreoSG Co.,Ltd. was founded in 1997 and is headquartered in Seoul, South Korea.

Recent A040350 News & Updates

Recent updates

No updates

CreoSG Co.,Ltd. Competitors

A018260 logo

Samsung SDS

Symbol: KOSE:A018260
Market cap: ₩17.6t
A307950 logo

Hyundai Autoever

Symbol: KOSE:A307950
Market cap: ₩10.8t
A064400 logo

LG CNS

Symbol: KOSE:A064400
Market cap: ₩7.0t
A022100 logo

Posco Dx

Symbol: KOSE:A022100
Market cap: ₩3.4t
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide